# NBTXR3 with radiotherapy and anti-PD-1 treatment

Source: https://onco.cc/trials/nct03589339/  
OnCo record `nct03589339` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study injects NBTXR3 into tumors and activates it with radiation alongside immune treatment. It studies safety and early signs of activity.

## Summary

This early study injects NBTXR3 into tumors and activates it with radiation alongside immune treatment. It studies safety and early signs of activity.

Interventional study registered as NCT03589339, sponsored by Nanobiotix. Registry phase: 1. Registry enrollment is 145 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT03589339
- Phase: 1
- Setting: Advanced cancers treated with anti-PD-1 therapy
- Sponsor: Nanobiotix

## Sources

- ClinicalTrials.gov NCT03589339: https://clinicaltrials.gov/study/NCT03589339
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT03589339

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [NBTXR3 (hafnium oxide nanoparticles)](https://onco.cc/drugs/nbtxr3/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct03589339.json